Market Cap 22.47M
Revenue (ttm) 0.00
Net Income (ttm) -66.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 19,900
Avg Vol 44,242
Day's Range N/A - N/A
Shares Out 40.85M
Stochastic %K 47%
Beta -0.61
Analysts Sell
Price Target $5.50

Company Profile

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis...

Industry: Biotechnology
Sector: Healthcare
Phone: 443 917 0966
Address:
20400 Century Boulevard, Suite 210, Germantown, United States
skyrockets_Inc
skyrockets_Inc Apr. 7 at 6:19 PM
$NEUP Both the $GLTO and $BRNS CEO's sent me similiar responses and then the deal was announced with 10 days of each of them...so assuming timing is always iffy. But this is a good, solid response. Thanks for sharing.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 20 at 5:00 AM
$BRNS Q4 '25 Earnings Results & Recap Barinthus Biotherapeutics PLC expects to incur net operating losses for at least the next several years as it advances product candidates and anticipates its existing cash, cash equivalents, and restricted cash will fund operations for at least 12 months.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 10:13 AM
$BRNS Current Stock Price: $0.58
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 6:29 PM
$BRNS RSI: 32.17, MACD: -0.0353 Vol: 0.06, MA20: 0.66, MA50: 0.70 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
floatchad
floatchad Feb. 20 at 4:24 PM
$BRNS Burns & McDonnell microcap exposure. Fundamentals are unclear. Liquidity risk dominates.
0 · Reply
johnnygogogo
johnnygogogo Feb. 12 at 11:29 PM
$BRNS hello? Anyone? Bueller?
0 · Reply
YoloYinYang
YoloYinYang Feb. 9 at 3:02 PM
$BRNS Brain stimulation or neuroscience tech; unproven commercial application.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 7:53 PM
$BRNS RSI: 48.09, MACD: -0.0066 Vol: 0.02, MA20: 0.73, MA50: 0.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 31 at 5:41 PM
0 · Reply
DeltaDomain
DeltaDomain Dec. 25 at 4:12 PM
$BRNS Macro forces may influence direction, yet internal execution remains the decisive factor. Reliability of results matters more than short bursts of momentum. Visible traction across segments would strengthen the thesis. Over time, credibility will hinge on repeatable performance.
0 · Reply
Latest News on BRNS
Vaccitech Promotes Gemma Brown as Chief Financial Officer

Sep 20, 2022, 4:30 PM EDT - 3 years ago

Vaccitech Promotes Gemma Brown as Chief Financial Officer


Vaccitech to Present at the Jefferies Healthcare Conference

Jun 6, 2022, 4:15 PM EDT - 4 years ago

Vaccitech to Present at the Jefferies Healthcare Conference


skyrockets_Inc
skyrockets_Inc Apr. 7 at 6:19 PM
$NEUP Both the $GLTO and $BRNS CEO's sent me similiar responses and then the deal was announced with 10 days of each of them...so assuming timing is always iffy. But this is a good, solid response. Thanks for sharing.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 20 at 5:00 AM
$BRNS Q4 '25 Earnings Results & Recap Barinthus Biotherapeutics PLC expects to incur net operating losses for at least the next several years as it advances product candidates and anticipates its existing cash, cash equivalents, and restricted cash will fund operations for at least 12 months.
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 10:13 AM
$BRNS Current Stock Price: $0.58
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 6:29 PM
$BRNS RSI: 32.17, MACD: -0.0353 Vol: 0.06, MA20: 0.66, MA50: 0.70 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
floatchad
floatchad Feb. 20 at 4:24 PM
$BRNS Burns & McDonnell microcap exposure. Fundamentals are unclear. Liquidity risk dominates.
0 · Reply
johnnygogogo
johnnygogogo Feb. 12 at 11:29 PM
$BRNS hello? Anyone? Bueller?
0 · Reply
YoloYinYang
YoloYinYang Feb. 9 at 3:02 PM
$BRNS Brain stimulation or neuroscience tech; unproven commercial application.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 7:53 PM
$BRNS RSI: 48.09, MACD: -0.0066 Vol: 0.02, MA20: 0.73, MA50: 0.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 31 at 5:41 PM
0 · Reply
DeltaDomain
DeltaDomain Dec. 25 at 4:12 PM
$BRNS Macro forces may influence direction, yet internal execution remains the decisive factor. Reliability of results matters more than short bursts of momentum. Visible traction across segments would strengthen the thesis. Over time, credibility will hinge on repeatable performance.
0 · Reply
Zaga64
Zaga64 Dec. 19 at 6:40 PM
$BRNS I'm trying to buy but I'm getting this message. Your order is not eligible for electronic entry. Please call a Charles Schwab representative at (800) 435-4000 for assistance with this trade. (AC4205)
0 · Reply
prismmarketview
prismmarketview Dec. 10 at 8:11 PM
Barinthus $BRNS reports positive Phase 1 results for VTP-1000 in celiac disease prismmarketview.com/barinth......
0 · Reply
DARKP00L
DARKP00L Dec. 10 at 1:33 PM
$BRNS 08:02 on Dec. 10 2025 Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease #tradeideas
0 · Reply
frontiere
frontiere Dec. 9 at 7:47 PM
$BRNS Barinthus to-be-merged w Clywedog Therapeutics $CLYD — ref=$0.699 Ling now small size — thanks @Alorenz94 for these summaries, look forward to Ph1 VTP-1000 SAD data imminently per Co guidance👍. 🚩Likely disappoint / negative! BUT - 👍already trades at HALF of run-rate cash (~$1.30 cash per sh run rate, 75.67m/40m=$1.89 cash per sh as of 2025-09-30, NEG EV), 👍near historical floor of $0.64, w CLYD merger in 1H26 w backing of prominent bio funds👍. Think here is attractive risk:return setup for either a short term swing or if too negative then a longer term swing. My prior https://stocktwits.com/frontiere/message/621170226
1 · Reply
topstockalerts
topstockalerts Dec. 8 at 12:21 PM
Pre Market Top Gainers PT2 $MTVA $FULC $PAVS $CFLT $BRNS
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 4 at 1:25 PM
$BRNS good addressed the 0.73 issue overlap u causing some issues for markets and beloved its done thanks make it up to u maybe later
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 4 at 12:44 PM
$BRNS rearranging this 0.73 now
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 4 at 12:43 PM
$BRNS noticed some restriction from your end on beloved will have to fix this 0.73* rewire it altogether
0 · Reply
elmono
elmono Nov. 18 at 10:49 PM
$BRNS going sub 40 cts soon…..
0 · Reply
Alorenz94
Alorenz94 Nov. 18 at 7:41 AM
$BRNS 4 possible scenarios for the VTP-1000 readout. Asked chat to do a probability weighted expected price on: A) strong positive data B) positive but not mind blowing data C) mixed data/inconclusive D) bad/negative Used the price range midpoint for each scenario. Outcome is as follow - $1.91/ share. This excludes merger price action, CLY’s pipeline, and the mentioned stock buyback so upside is likely way higher than $1.91/share.
2 · Reply
Alorenz94
Alorenz94 Nov. 18 at 2:33 AM
$BRNS …..As of the recent Q325 earnings PR, PH 1 SAD is “ongoing with no treatment related serious adverse events reported” (positive indicator for the drug’s safety profile). And 4 clinical data milestones expected within 18mo of the closing of the transaction in 1H 2026. Need closing to be early Q1 lol. Bleeding ATM. H.C. wainwright analyst Yi Chen reiterated his BUY rating on BRNS today and set a PT Of $4/ share today as well for what it’s worth
0 · Reply